August 29, 2025

LHON UK Treatment Approved

NICE approves first treatment for Leber’s hereditary optic neuropathy in England

The Ophthalmologist

August 28, 2025

Continuous Immunoglobulin E Ranges Set for Children

Study establishes age-specific reference intervals for healthy and allergic children

The Pathologist

August 28, 2025

The Surprising Origins of Pathology – and the Future No One Saw Coming

How historical figures shaped modern diagnostics – and how their spirit lives on in today’s innovators

The Pathologist

August 27, 2025

Clinical Trials and Research for Mantle Cell Lymphoma

Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma.

Dana-Farber

August 27, 2025

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, ...

The ASCO Post

August 26, 2025

From Biopsy to Bedside in a Week: Inside the GUSTO Trial 

Can gene expression subtyping be used to guide treatment decisions for bladder cancer?

The Pathologist

August 22, 2025

Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer...

The ASCO Post

August 22, 2025

Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship

Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology. 

The ASCO Post

August 22, 2025

Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease

The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with standard radiation therapy and temozolomide for patients wi...

The ASCO Post